第11批国家组织药品集采报量：回应临床真实需求

Core Viewpoint - The recent launch of the 11th batch of national drug centralized procurement emphasizes the importance of accurate reporting by medical institutions, introducing new rules to accommodate diverse medication needs while allowing for independent procurement of non-selected drugs outside the procurement agreement [2][5]. Group 1: Reporting Rules and Requirements - The reporting period for this centralized procurement is from August 6 to August 25, requiring participation from all public and military medical institutions [2]. - New reporting rules allow medical institutions to report either by drug name or by brand, providing flexibility in meeting clinical needs [2][4]. - Institutions can choose to report some drugs by name and others by brand, with no limit on the number of brands that can be reported [2]. Group 2: Demand Determination and Procurement - Medical institutions must consider clinical demand changes and ensure that total reported quantities are not less than 80% of the average procurement volume for 2023 and 2024 [4]. - For drugs with increasing usage trends, institutions are encouraged to report quantities at or above 100% of historical averages, while those with limited indications can report lower quantities based on actual usage [4]. - Institutions are allowed to adjust reported quantities based on specific circumstances, such as departmental changes or temporary usage [4]. Group 3: Procurement Flexibility and Market Dynamics - Institutions are encouraged to prioritize selected drugs but are not restricted to them; they can procure non-selected drugs based on actual needs [5]. - Since 2018, a total of 435 drugs have been procured through 10 batches of centralized procurement, which has helped reduce costs for patients and facilitated the inclusion of new drugs in the medical insurance list [5]. - The procurement process aims to maintain clinical stability, ensure quality, and prevent unethical practices such as collusion among suppliers [5].